Background The GetGoal-L-Asia and -S trials were multi-center trials conducted in 4 and 16 countries, respectively including Japan that evaluated the efficacy and safety of lixisenatide add-on treatment vs. populace of Japanese type 2 diabetes patients included 143 patients (mean age: 59.0?years; 35?% female) treated with lixisenatide and 136 patients treated with placebo (mean age:… Continue reading Background The GetGoal-L-Asia and -S trials were multi-center trials conducted in